The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

CARGO Therapeutics, Inc. (CRGX) has received a new Buy rating, initiated by William Blair analyst, Sami Corwin.Don't Miss our Black Friday ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no ...

The Lehigh Valley Topper Cancer institute has announced that it is now offering treatment using autologous chimeric antigen ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data ...

Kokumi refers to the enhanced and more delicious state of food flavor. However, the underlying neuroscientific mechanisms remain largely unexplored. Our previous research demonstrated that ornithine ...

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.